NewsBlack Swan Analysis Are Exhibiting at BHBIA 2019

Black Swan Analysis Are Exhibiting at BHBIA 2019

By Black Swan Analysis 31st October 2019

BHBIA 2019 will be held on the 13-14th May 2019, at the De Vere Beaumont Estate, Old Windsor, Berkshire, attracting around 280 delegates from across the spectrum of healthcare business intelligence (market research, business information, commercial analytics, sales force effectiveness) and allied fields. The BHBIA Annual Conference is a members' only event - open to BHBIA Corporate, Affiliate and Personal members only.

Please see the details below:

Date: 13-14 May 2019

Display Hours: 9am-4.15pm

Booth Number: 15

Attendees: Nic Talbot Watt (CEO), Charles Fidler (Analyst), Greg Higgins (Senior Epidemiology Analyst).

We look forward to seeing you at #BHBIA19

Get in touch to find out how we can help

Get in touch

Related blogs and resources

Top Sources Of Epidemiological Data

Finding and properly assessing strong sources of epidemiological data is becoming more and more important in this age of evidence-based medicine. With a general shift towards a focus on more niche and rarer diseases within the pharmaceutical industry, there is a growing need for accurate and relevant data. With a smaller amount of general data...

Vertex Cystic Fibrosis Drugs approved for NHS use after 3-year financial dispute

On October the 24th 2019, the NHS reported a licensing agreement with Vertex Pharmaceutical’s range of Cystic Fibrosis (CF) treatments (NHS England, 2019). This comes after a series of failed financial negotiations, in which the NHS did not deem the approval of CF drugs Orkambi and Symkevi as good value for the British taxpayers (Staines, 2019)....

Modulating toxicity in photodynamic treatment (PDT, light activated) and improving imaging quality of theranostic(a) compounds to diagnose and treat cancer.

Over the past two decades an array of targeted therapies have begun to revolutionise cancer treatment, providing better clinical outcomes in tumour types which exhibit certain biomarkers In contrast with traditional broad cytotoxic chemotherapies. Targeted therapies while more selective as inhibitors of cancer cell survival, can still have broad and severe side effect profiles for...

Consultancy

Related blogs and resources

Top Sources Of Epidemiological Data

Vertex Cystic Fibrosis Drugs approved for NHS use after 3-year financial dispute

Modulating toxicity in photodynamic treatment (PDT, light activated) and improving imaging quality of theranostic(a) compounds to diagnose and treat cancer.

Cookies